Apollo Medical Holdings, Inc(NASDAQ:AMEH) 
Apollo Medical Holdings, Inc., a physician-centric technology-powered healthcare management company, provides medical care services. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which emp...
Website: http://www.apollomed.net
Founded: 1985
Full Time Employees: 547
Sector: Healthcare
Industry: Medical Care Facilities
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue | |||||||||||||||||||||||
yoy | |||||||||||||||||||||||
qoq | |||||||||||||||||||||||
capitation | 892,908,000 | 862,814,000 | 863,380,000 | 614,108,000 | 583,963,000 | 616,900,000 | 431,401,000 | 442,574,000 | 365,910,000 | 309,184,000 | 305,678,000 | 300,549,000 | 300,204,000 | 252,878,000 | 227,571,000 | 227,623,000 | 222,060,000 | 154,874,000 | 149,059,000 | 144,550,000 | 144,740,000 | 140,924,000 | 135,032,000 |
risk pool settlements and incentives | 12,486,000 | 25,508,000 | 30,798,000 | 15,402,000 | 14,491,000 | 28,660,000 | 21,779,000 | 18,408,000 | 17,377,000 | 14,863,000 | 15,022,000 | 20,121,000 | 13,462,000 | 15,537,000 | 64,849,000 | 18,793,000 | 18,075,000 | 17,481,000 | 59,923,000 | 16,214,000 | 18,010,000 | 23,212,000 | 30,916,000 |
management fee income | 15,685,000 | 10,290,000 | 15,217,000 | 2,577,000 | 2,310,000 | 5,550,000 | 2,747,000 | 1,604,000 | 4,078,000 | 6,390,000 | 9,898,000 | 12,493,000 | 9,896,000 | 10,607,000 | 10,030,000 | 9,984,000 | 10,473,000 | 9,614,000 | 9,652,000 | 8,143,000 | 8,550,000 | 8,638,000 | 8,707,000 |
fee-for-service | 37,831,000 | 39,787,000 | 40,080,000 | 17,878,000 | 14,890,000 | 7,743,000 | 18,692,000 | 19,959,000 | 15,937,000 | 18,442,000 | 15,892,000 | 13,262,000 | 12,062,000 | 13,823,000 | 12,859,000 | 11,740,000 | 11,095,000 | 11,596,000 | 7,260,000 | 4,621,000 | 3,086,000 | 3,249,000 | 3,737,000 |
other revenue | 6,190,000 | 12,127,000 | 6,573,000 | 4,843,000 | 4,736,000 | 6,356,000 | 4,091,000 | 3,720,000 | 1,054,000 | 4,157,000 | 1,683,000 | 1,784,000 | |||||||||||
total revenue | 965,100,000 | 950,526,000 | 956,048,000 | 654,808,000 | 620,390,000 | 665,209,000 | 478,710,000 | 486,265,000 | 404,356,000 | 353,036,000 | 348,173,000 | 348,209,000 | 337,244,000 | 294,208,000 | 317,001,000 | 269,697,000 | 263,258,000 | 195,100,000 | 227,117,000 | 175,638,000 | 176,058,000 | 176,783,000 | 180,123,000 |
operating expenses | |||||||||||||||||||||||
cost of services, excluding depreciation and amortization | 859,356,000 | 855,483,000 | 858,856,000 | 576,839,000 | 549,061,000 | 614,730,000 | 405,218,000 | 412,805,000 | 330,399,000 | 314,055,000 | 275,375,000 | 292,876,000 | 289,397,000 | 253,119,000 | 240,768,000 | 230,070,000 | 220,730,000 | 171,839,000 | 147,473,000 | 136,214,000 | 140,616,000 | ||
general and administrative expenses | 61,737,000 | 60,247,000 | 62,387,000 | 50,725,000 | 43,897,000 | 41,633,000 | 37,803,000 | 35,953,000 | 38,722,000 | 37,949,000 | 29,410,000 | 24,056,000 | 21,182,000 | 24,446,000 | 21,388,000 | 19,894,000 | 11,943,000 | 16,601,000 | 21,813,000 | 14,199,000 | 9,464,000 | 9,456,000 | 16,270,000 |
depreciation and amortization | 15,479,000 | 16,401,000 | 15,595,000 | 6,904,000 | 6,849,000 | 8,126,000 | 7,264,000 | 7,441,000 | 5,096,000 | 4,902,000 | 4,305,000 | 4,248,000 | 4,292,000 | 4,063,000 | 4,754,000 | 4,351,000 | 4,374,000 | 4,412,000 | 4,671,000 | 4,237,000 | 4,197,000 | 4,346,000 | 4,674,000 |
total expenses | 936,572,000 | 932,131,000 | 936,838,000 | 634,468,000 | 599,807,000 | 664,489,000 | 450,285,000 | 456,199,000 | 374,217,000 | 356,906,000 | 309,090,000 | 321,180,000 | 314,871,000 | 281,628,000 | 266,910,000 | 254,315,000 | 237,047,000 | 192,852,000 | 173,957,000 | 154,650,000 | 154,277,000 | 150,907,000 | 142,767,000 |
income from operations | 28,528,000 | 18,395,000 | 19,210,000 | 20,340,000 | 20,583,000 | 720,000 | 28,425,000 | 30,066,000 | 30,139,000 | -3,870,000 | 39,083,000 | 27,029,000 | 22,373,000 | 12,580,000 | 50,091,000 | 15,382,000 | 26,211,000 | 2,248,000 | 53,160,000 | 20,988,000 | 21,781,000 | 25,876,000 | 37,356,000 |
yoy | 38.60% | 2454.86% | -32.42% | -32.35% | -31.71% | -118.60% | -27.27% | 11.24% | 34.71% | -130.76% | -21.98% | 75.72% | -14.64% | 459.61% | -5.77% | -26.71% | 20.34% | -91.31% | 42.31% | ||||
qoq | 55.09% | -4.24% | -5.56% | -1.18% | 2758.75% | -97.47% | -5.46% | -0.24% | -878.79% | -109.90% | 44.60% | 20.81% | 77.85% | -74.89% | 225.65% | -41.31% | 1065.97% | -95.77% | 153.29% | -3.64% | -15.83% | -30.73% | |
operating margin % | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
other income | 662,000 | 699,000 | 445,000 | 1,136,000 | 353,000 | 2,673,000 | 6,126,000 | -4,277,000 | 1,856,000 | 1,876,000 | 1,185,000 | 1,620,000 | 1,363,000 | 1,692,000 | 1,557,000 | 1,555,000 | 1,535,000 | 1,223,000 | 2,110,000 | 1,672,000 | 760,000 | 1,731,000 | |
income from equity method investments | 1,720,000 | 1,176,000 | 1,019,000 | 381,000 | -867,000 | 1,564,000 | 1,353,000 | 902,000 | 632,000 | 2,475,000 | -2,104,000 | 2,723,000 | 2,484,000 | 1,225,000 | 1,452,000 | 1,512,000 | 1,433,000 | -626,000 | 132,000 | -3,134,000 | -677,000 | 403,000 | 403,000 |
interest expense | -16,101,000 | -17,520,000 | -17,718,000 | -7,382,000 | -7,308,000 | -8,069,000 | -8,856,000 | -8,587,000 | -7,585,000 | -5,422,000 | -3,779,000 | -3,632,000 | -3,269,000 | -2,572,000 | -2,422,000 | -1,854,000 | -1,073,000 | -1,051,000 | -967,000 | -1,853,000 | -1,523,000 | -1,492,000 | -2,466,000 |
interest income | 3,816,000 | 3,987,000 | 3,522,000 | 2,336,000 | 2,312,000 | 3,221,000 | 3,778,000 | 3,513,000 | 3,996,000 | 4,591,000 | 3,281,000 | 3,327,000 | 3,009,000 | 1,286,000 | 223,000 | 421,000 | 46,000 | 240,000 | 420,000 | 563,000 | 349,000 | 269,000 | 752,000 |
unrealized gain on investments | 1,084,000 | 769,000 | -807,000 | 14,000 | -44,000 | 316,000 | -561,000 | -123,000 | 1,099,000 | 859,000 | -4,397,750 | -6,763,000 | -1,866,000 | 5,706,500 | -60,943,000 | ||||||||
total other expense | -8,819,000 | -7,007,500 | -13,539,000 | -10,979,000 | -2,964,000 | -7,943,000 | |||||||||||||||||
income before provision for income taxes | 19,709,000 | 7,506,000 | 5,671,000 | 16,825,000 | 9,604,000 | -1,895,000 | 26,812,000 | 31,897,000 | 24,004,000 | 924,000 | 38,015,000 | 31,491,000 | 19,409,000 | 10,455,000 | 41,263,000 | 16,629,000 | 18,268,000 | -22,430,000 | -5,505,000 | 84,450,000 | 21,234,000 | 24,811,000 | 36,175,000 |
provision for income taxes | 6,578,000 | 944,000 | 4,594,000 | 6,609,000 | 3,383,000 | 5,882,000 | 7,831,000 | 10,031,000 | 7,142,000 | 1,018,000 | 10,042,000 | 14,009,000 | 5,102,000 | 9,984,000 | 13,867,000 | 6,038,000 | 6,195,000 | -3,121,000 | -120,000 | 24,920,000 | 6,776,000 | 11,903,000 | 10,751,000 |
net income | 13,131,000 | 6,562,000 | 1,077,000 | 10,216,000 | 6,221,000 | -7,777,000 | 18,981,000 | 21,866,000 | 16,862,000 | -94,000 | 27,973,000 | 17,482,000 | 14,307,000 | 471,000 | 27,396,000 | 10,591,000 | 12,073,000 | -19,309,000 | -5,385,000 | 59,530,000 | 14,458,000 | 12,908,000 | 25,424,000 |
yoy | 111.08% | -184.38% | -94.33% | -53.28% | -63.11% | 8173.40% | -32.15% | 25.08% | 17.86% | -119.96% | 2.11% | 65.06% | 18.50% | -102.44% | -608.75% | -82.21% | -16.50% | -249.59% | -121.18% | ||||
qoq | 100.11% | 509.29% | -89.46% | 64.22% | -179.99% | -140.97% | -13.19% | 29.68% | -18038.30% | -100.34% | 60.01% | 22.19% | 2937.58% | -98.28% | 158.67% | -12.28% | -162.53% | 258.57% | -109.05% | 311.74% | 12.01% | -49.23% | |
net income margin % | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
net loss attributable to non-controlling interests | -1,305,000 | ||||||||||||||||||||||
net income attributable to astrana health, inc. | 14,436,000 | 5,999,000 | 373,000 | 9,423,000 | 6,692,000 | -6,951,000 | 16,094,000 | 19,171,000 | 14,835,000 | ||||||||||||||
earnings per share – basic | 0.3 | 0.12 | 0.01 | 0.19 | 0.14 | -0.14 | 0.34 | 0.4 | 0.31 | 0.26 | 0.47 | 0.28 | 0.31 | -0.06 | 0.58 | 0.25 | 0.32 | 0.31 | 0.77 | 0.29 | 0.31 | 0.27 | 0.46 |
earnings per share – diluted | 0.29 | 0.13 | 0.01 | 0.19 | 0.14 | -0.14 | 0.33 | 0.4 | 0.31 | 0.26 | 0.47 | 0.28 | 0.31 | -0.04 | 0.56 | 0.25 | 0.31 | 0.3 | 0.74 | 0.28 | 0.3 | 0.26 | 0.45 |
net income attributable to non-controlling interest | 256,500 | 704,000 | 793,000 | -471,000 | 1,902,250 | 2,887,000 | 2,695,000 | 2,027,000 | 2,395,500 | 5,914,000 | 4,312,000 | -397,250 | 1,410,000 | -808,000 | -2,191,000 | ||||||||
total other income | -3,515,000 | -2,615,000 | -1,613,000 | 4,794,000 | -1,068,000 | 4,462,000 | -2,125,000 | -8,828,000 | 1,247,000 | -24,678,000 | -58,665,000 | 63,462,000 | -547,000 | -1,065,000 | -1,181,000 | ||||||||
other expense | |||||||||||||||||||||||
other loss | -5,072,000 | ||||||||||||||||||||||
total other income (expenses) | 1,831,000 | ||||||||||||||||||||||
total other expenses | -6,135,000 | ||||||||||||||||||||||
unrealized loss on investments | 1,294,000 | -342,000 | -6,392,000 | -8,962,000 | |||||||||||||||||||
net income attributable to apollo medical holdings, inc. | 12,090,250 | 22,059,000 | 13,170,000 | 14,622,000 | -2,600,000 | 25,986,000 | 11,399,000 | 14,264,000 | 13,770,000 | 34,279,000 | 12,658,000 | 13,151,000 | 10,057,000 | 16,713,000 | |||||||||
weighted-average shares used for eps calculation | |||||||||||||||||||||||
basic | 46,547,502 | ||||||||||||||||||||||
diluted | 46,920,607 | ||||||||||||||||||||||
net loss attributable to non-controlling interest | -315,000 | ||||||||||||||||||||||
gain on sale of equity method investment | 2,193,000 | 192,000 | |||||||||||||||||||||
net income attributable to noncontrolling interest | 2,128,750 | -39,664,000 | 46,872,000 | 1,307,000 | 20,400,750 | 8,711,000 | |||||||||||||||||
cost of services | 100,526,500 | 121,823,000 | |||||||||||||||||||||
provision for doubtful accounts | |||||||||||||||||||||||
impairment of intangibles |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||
current assets | ||||||||||||||||||||||
cash and cash equivalents | 478,383,000 | 429,474,000 | 462,227,000 | 339,703,000 | 258,517,000 | 288,455,000 | 347,994,000 | 325,310,000 | 334,796,000 | 293,807,000 | 273,941,000 | 293,921,000 | 274,613,000 | 184,016,000 | 234,223,000 | 237,942,000 | 233,097,000 | 204,768,000 | 177,287,000 | 205,876,000 | 193,470,000 | 166,082,000 |
receivables | 467,395,000 | 374,465,000 | 381,215,000 | 348,730,000 | 241,078,000 | 225,733,000 | 132,237,000 | 132,323,000 | 120,106,000 | 76,780,000 | 95,892,000 | 66,927,000 | 79,003,000 | 69,386,000 | 67,263,000 | 55,280,000 | 10,608,000 | 18,753,000 | 16,540,000 | 16,448,000 | 7,058,000 | 18,257,000 |
income taxes receivable | 1,799,000 | 7,893,000 | 15,802,000 | 19,316,000 | 16,211,000 | 22,005,000 | 10,657,000 | 15,943,000 | 9,000 | 12,224,000 | 12,639,000 | |||||||||||
other receivables | 28,017,000 | 26,385,000 | 9,891,000 | 8,655,000 | 14,919,000 | 29,496,000 | 1,120,000 | 1,642,000 | 1,783,000 | 1,335,000 | 1,501,000 | 1,201,000 | 1,929,000 | 41,799,000 | 13,227,000 | 13,260,000 | 9,647,000 | 5,773,000 | 4,562,000 | 4,518,000 | 4,297,000 | 3,988,000 |
prepaid expenses and other current assets | 25,647,000 | 26,264,000 | 23,162,000 | 21,754,000 | 23,711,000 | 22,861,000 | 20,506,000 | 17,417,000 | 17,281,000 | 17,450,000 | 13,953,000 | 15,087,000 | 22,170,000 | 11,702,000 | 12,670,000 | 14,631,000 | 18,637,000 | 11,734,000 | 12,188,000 | 9,630,000 | 16,747,000 | 12,119,000 |
loans receivable | 4,658,000 | 4,926,000 | 5,913,000 | 973,000 | 973,000 | 973,000 | 518,000 | 539,000 | 549,000 | 569,000 | 584,000 | 480,000 | 480,000 | |||||||||
total current assets | 1,004,100,000 | 863,313,000 | 883,629,000 | 729,152,000 | 613,270,000 | 638,496,000 | 596,990,000 | 570,349,000 | 538,810,000 | 461,507,000 | 476,229,000 | 465,063,000 | 457,688,000 | 443,616,000 | 461,038,000 | 444,416,000 | 398,782,000 | 427,212,000 | 470,550,000 | 370,275,000 | 338,577,000 | 366,698,000 |
non-current assets | ||||||||||||||||||||||
property and equipment | 59,546,000 | 57,332,000 | 56,164,000 | 17,800,000 | 16,849,000 | 14,274,000 | ||||||||||||||||
intangible assets | 257,118,000 | 270,968,000 | 285,060,000 | 105,737,000 | 111,916,000 | 118,179,000 | 109,108,000 | 116,231,000 | 119,707,000 | 71,648,000 | 74,209,000 | 74,421,000 | 77,675,000 | 73,231,000 | 76,651,000 | 80,148,000 | 82,807,000 | 83,594,000 | 80,227,000 | 83,199,000 | 86,985,000 | 90,781,000 |
goodwill | 874,799,000 | 865,305,000 | 863,266,000 | 416,917,000 | 416,386,000 | 419,253,000 | 409,711,000 | 409,581,000 | 410,267,000 | 278,831,000 | 275,528,000 | 274,029,000 | 276,028,000 | 257,482,000 | 253,310,000 | 252,379,000 | 253,039,000 | 243,353,000 | 239,053,000 | 239,053,000 | 239,053,000 | 239,053,000 |
income taxes receivable, net of current portion | 26,220,000 | 26,220,000 | ||||||||||||||||||||
loans receivable, net of current portion | 49,068,000 | 48,724,000 | ||||||||||||||||||||
investments in other entities – equity method | 27,257,000 | 25,637,000 | 18,462,000 | 38,454,000 | 38,005,000 | 39,319,000 | 34,629,000 | 33,276,000 | 35,893,000 | 25,774,000 | 44,428,000 | 45,831,000 | 43,108,000 | 38,954,000 | 43,820,000 | 44,383,000 | 41,715,000 | 45,046,000 | 43,292,000 | |||
operating lease right-of-use assets | 33,933,000 | 35,738,000 | 33,936,000 | 30,631,000 | 30,698,000 | 32,601,000 | 33,119,000 | 28,792,000 | 39,152,000 | 37,396,000 | 21,482,000 | 17,905,000 | 18,431,000 | 16,338,000 | 19,638,000 | 14,770,000 | 15,441,000 | 16,134,000 | 16,928,000 | 17,738,000 | 18,574,000 | 19,298,000 |
other assets | 26,786,000 | 22,528,000 | 23,356,000 | 30,450,000 | 30,512,000 | 16,021,000 | 8,878,000 | 9,289,000 | 4,067,000 | 1,877,000 | 8,586,000 | 7,229,000 | 5,441,000 | 6,097,000 | 5,901,000 | 4,424,000 | 5,928,000 | 5,195,000 | 8,072,000 | 19,107,000 | 18,915,000 | 22,473,000 |
total non-current assets | 1,354,727,000 | 1,355,348,000 | 1,353,557,000 | 713,198,000 | 717,986,000 | 716,398,000 | 688,386,000 | 682,122,000 | 687,467,000 | 471,854,000 | 597,032,000 | 562,113,000 | 534,940,000 | 499,790,000 | 490,026,000 | 467,915,000 | 453,581,000 | |||||
total assets | 2,358,827,000 | 2,218,661,000 | 2,237,186,000 | 1,442,350,000 | 1,331,256,000 | 1,354,894,000 | 1,285,376,000 | 1,252,471,000 | 1,226,277,000 | 933,361,000 | 1,073,261,000 | 1,027,176,000 | 992,628,000 | 943,406,000 | 951,064,000 | 912,331,000 | 852,363,000 | 871,294,000 | 894,430,000 | 843,280,000 | 817,486,000 | 814,273,000 |
liabilities, mezzanine deficit, and stockholders’ equity | ||||||||||||||||||||||
current liabilities | ||||||||||||||||||||||
accounts payable and accrued expenses | 221,389,000 | 195,912,000 | 209,747,000 | 119,661,000 | 105,559,000 | 106,142,000 | 94,811,000 | 95,757,000 | 146,473,000 | 59,949,000 | 53,136,000 | 49,904,000 | 49,486,000 | 47,366,000 | 59,922,000 | 48,252,000 | 43,951,000 | 57,505,000 | 53,792,000 | 40,234,000 | 36,143,000 | 40,474,000 |
fiduciary accounts payable | 3,706,000 | 3,524,000 | 4,476,000 | 4,734,000 | 4,840,000 | 8,223,000 | 6,041,000 | 7,321,000 | 7,792,000 | 7,737,000 | 6,257,000 | 8,603,000 | 8,976,000 | 6,506,000 | 6,071,000 | 6,305,000 | 10,534,000 | 8,827,000 | 9,092,000 | 6,871,000 | 9,642,000 | 3,986,000 |
income taxes payable | 2,507,000 | 4,919,000 | 5,522,000 | 30,112,000 | 20,354,000 | 4,894,000 | 652,000 | 4,024,000 | 2,215,000 | 12,059,000 | 4,224,000 | 16,169,000 | ||||||||||
medical liabilities | 439,259,000 | 335,705,000 | 333,969,000 | 287,691,000 | 204,101,000 | 209,039,000 | 160,279,000 | 151,482,000 | 136,494,000 | 106,657,000 | 97,519,000 | 100,047,000 | 101,394,000 | 94,884,000 | 112,499,000 | 95,758,000 | 55,783,000 | 42,872,000 | 59,307,000 | 51,479,000 | 50,330,000 | 57,455,000 |
operating lease liabilities | 7,557,000 | 7,809,000 | 7,181,000 | 5,319,000 | 4,979,000 | 5,350,000 | 5,241,000 | 4,884,000 | 5,007,000 | 4,607,000 | 3,528,000 | 3,027,000 | 3,234,000 | 3,208,000 | 3,253,000 | 2,625,000 | 2,629,000 | 2,658,000 | 2,831,000 | 3,036,000 | 3,177,000 | 3,290,000 |
current portion of long-term debt | 47,865,000 | 47,865,000 | 47,865,000 | 12,500,000 | 12,500,000 | 9,375,000 | 15,000,000 | 17,000,000 | 20,750,000 | 19,500,000 | 2,991,000 | 2,630,000 | 621,000 | 1,503,000 | 780,000 | 12,078,000 | 10,889,000 | |||||
other liabilities | 23,086,000 | 24,458,000 | 21,773,000 | 29,841,000 | 28,180,000 | 26,287,000 | 30,364,000 | 32,152,000 | 31,960,000 | 18,940,000 | 8,121,000 | |||||||||||
total current liabilities | 745,369,000 | 615,273,000 | 629,930,000 | 459,746,000 | 361,268,000 | 365,608,000 | 312,928,000 | 309,825,000 | 355,272,000 | 218,674,000 | 202,957,000 | 185,794,000 | 164,954,000 | 115,371,000 | 114,992,000 | |||||||
non-current liabilities | ||||||||||||||||||||||
deferred tax liability | 7,399,000 | 5,491,000 | 4,429,000 | 2,593,000 | 4,197,000 | 2,857,000 | 3,250,000 | 3,756,000 | 4,072,000 | 12,145,000 | 12,335,000 | 3,695,000 | 9,127,000 | 10,959,000 | ||||||||
operating lease liabilities, net of current portion | 30,006,000 | 31,552,000 | 30,171,000 | 28,714,000 | 28,963,000 | 31,162,000 | 27,092,000 | 37,716,000 | 36,289,000 | 21,006,000 | 17,852,000 | 18,164,000 | 13,198,000 | 15,865,000 | ||||||||
long-term debt | 979,764,000 | 990,904,000 | 1,002,026,000 | 401,057,000 | 403,894,000 | 423,119,000 | 425,006,000 | 368,448,000 | 258,939,000 | 206,213,000 | 205,136,000 | 204,944,000 | 182,917,000 | 230,211,000 | ||||||||
other long-term liabilities | 18,833,000 | 17,107,000 | 15,906,000 | 12,294,000 | 14,685,000 | 7,460,000 | 7,723,000 | 7,652,000 | 3,586,000 | 14,105,000 | 21,383,000 | 21,806,000 | 14,777,000 | |||||||||
total non-current liabilities | 1,036,002,000 | 1,045,054,000 | 1,052,532,000 | 444,658,000 | 452,282,000 | 465,341,000 | 463,950,000 | 418,587,000 | 303,919,000 | 254,664,000 | 257,784,000 | 249,745,000 | 220,992,000 | |||||||||
total liabilities | 1,781,371,000 | 1,660,327,000 | 1,682,462,000 | 904,404,000 | 813,550,000 | 778,269,000 | 773,775,000 | 773,859,000 | 522,593,000 | 457,621,000 | 443,578,000 | 414,699,000 | 336,363,000 | 372,338,000 | ||||||||
commitments and contingencies | ||||||||||||||||||||||
mezzanine deficit | ||||||||||||||||||||||
non-controlling interest in allied physicians of california, a professional medical corporation | -237,739,000 | -234,962,000 | -205,883,000 | 17,931,000 | 13,845,000 | 14,729,000 | 55,510,000 | |||||||||||||||
stockholders’ equity | ||||||||||||||||||||||
preferred stock, 0.001 par value per share... | ||||||||||||||||||||||
common stock, 0.001 par value per share... | 49,000 | 49,000 | 49,000 | 48,000 | 48,000 | 48,000 | 47,000 | 47,000 | 47,000 | |||||||||||||
additional paid-in capital | 477,508,000 | 470,863,000 | 463,203,000 | 411,334,000 | 401,686,000 | 395,473,000 | 371,037,000 | 362,889,000 | 357,246,000 | 352,697,000 | 310,876,000 | 261,011,000 | ||||||||||
retained earnings | 322,711,000 | 308,379,000 | 302,209,000 | 293,234,000 | 277,140,000 | 257,969,000 | 243,134,000 | 230,778,000 | 208,719,000 | 207,300,000 | 143,629,000 | 69,771,000 | ||||||||||
total stockholders’ equity | 800,268,000 | 779,291,000 | 765,461,000 | 704,616,000 | 678,874,000 | 653,490,000 | 616,651,000 | 593,714,000 | 566,012,000 | 560,044,000 | 460,490,000 | 330,911,000 | ||||||||||
non-controlling interests | 14,927,000 | |||||||||||||||||||||
total equity | 815,195,000 | 793,296,000 | 709,619,000 | 683,008,000 | 657,975,000 | 597,709,000 | 569,753,000 | 563,200,000 | ||||||||||||||
total liabilities, mezzanine deficit, and stockholders’ equity | 2,358,827,000 | 2,218,661,000 | ||||||||||||||||||||
investments in privately held entities | 2,896,000 | 8,896,000 | 8,896,000 | 8,896,000 | 8,896,000 | 8,896,000 | 8,896,000 | 6,396,000 | 6,396,000 | 2,896,000 | 2,896,000 | 896,000 | 896,000 | 896,000 | 896,000 | 896,000 | 896,000 | 896,000 | 37,075,000 | 37,075,000 | 37,075,000 | |
non-controlling interest | 14,005,000 | 5,003,000 | 4,134,000 | 4,485,000 | 2,433,000 | 3,995,000 | 3,741,000 | 3,156,000 | 5,940,000 | |||||||||||||
investment in marketable securities | 1,221,000 | 2,417,000 | 2,397,000 | 2,378,000 | 2,354,000 | 2,383,000 | 2,490,000 | 2,498,000 | 53,417,000 | 66,931,000 | 67,695,000 | 118,309,000 | ||||||||||
income taxes receivable, non-current | 15,943,000 | 15,943,000 | 15,943,000 | |||||||||||||||||||
loans receivable, non-current | 48,474,000 | 48,370,000 | 48,134,000 | 51,266,000 | 55,284,000 | 49,163,000 | 47,412,000 | 26,473,000 | ||||||||||||||
noncontrolling interest in allied physicians of california, a professional medical corporation | -233,582,000 | -202,512,000 | -204,312,000 | -205,557,000 | 114,237,000 | |||||||||||||||||
receivables, net – related parties | 56,846,000 | 50,257,000 | 76,568,000 | 69,269,000 | 62,354,000 | 58,980,000 | 86,948,000 | 82,820,000 | 74,877,000 | 91,208,000 | 81,526,000 | 76,410,000 | 69,376,000 | 53,626,000 | 68,767,000 | 66,872,000 | 49,260,000 | 41,518,000 | ||||
restricted cash | 647,000 | 646,000 | 646,000 | 646,000 | 645,000 | 345,000 | 345,000 | 345,000 | ||||||||||||||
dividend payable | 638,000 | 638,000 | 638,000 | 638,000 | 638,000 | 638,000 | 638,000 | 638,000 | 664,000 | 556,000 | 556,000 | 556,000 | 556,000 | 556,000 | 536,000 | 481,000 | 485,000 | 485,000 | ||||
finance lease liabilities | 471,000 | 554,000 | 554,000 | 591,000 | 636,000 | 646,000 | 655,000 | 591,000 | 579,000 | 509,000 | 524,000 | 543,000 | 486,000 | 110,000 | 110,000 | 109,000 | 102,000 | 102,000 | ||||
finance lease liabilities, net of current portion | 543,000 | 743,000 | 879,000 | 1,015,000 | 1,033,000 | 1,195,000 | 1,078,000 | 1,136,000 | 973,000 | 311,000 | ||||||||||||
land, property, and equipment | 12,172,000 | 128,575,000 | 123,859,000 | 113,361,000 | 104,149,000 | 87,146,000 | 70,366,000 | 49,280,000 | 40,738,000 | 29,609,000 | ||||||||||||
liabilities, mezzanine equity, and equity | ||||||||||||||||||||||
mezzanine equity | ||||||||||||||||||||||
series a preferred stock, zero authorized and issued and zero outstanding as of september 30, 2024 and 1,111,111 authorized and issued and zero outstanding as of december 31, 2023 | ||||||||||||||||||||||
series b preferred stock, zero authorized and issued and zero outstanding as of september 30, 2024 and 555,555 authorized and issued and zero outstanding as of december 31, 2023 | ||||||||||||||||||||||
total liabilities, mezzanine equity, and equity | 1,285,376,000 | |||||||||||||||||||||
land, property and equipment | 10,305,000 | 7,985,000 | 7,171,000 | 53,186,000 | 29,890,000 | 10,929,000 | ||||||||||||||||
liabilities, mezzanine equity and equity | ||||||||||||||||||||||
series a preferred stock, zero authorized and issued and zero outstanding as of june 30, 2024 and 1,111,111 authorized and issued and zero outstanding as of december 31, 2023 | ||||||||||||||||||||||
series b preferred stock, zero authorized and issued and zero outstanding as of june 30, 2024 and 555,555 authorized and issued and zero outstanding as of december 31, 2023 | ||||||||||||||||||||||
total liabilities, mezzanine equity and equity | 1,252,471,000 | 1,226,277,000 | 1,073,261,000 | 1,027,176,000 | 992,628,000 | |||||||||||||||||
series a preferred stock, 0.001 par value per share... | ||||||||||||||||||||||
series b preferred stock, 0.001 par value per share... | ||||||||||||||||||||||
loans receivable – related party | ||||||||||||||||||||||
astrana health, inc. | ||||||||||||||||||||||
consolidated balance sheets | ||||||||||||||||||||||
liabilities, mezzanine equity (deficit), and stockholders’ equity | ||||||||||||||||||||||
mezzanine (deficit) equity | ||||||||||||||||||||||
series a preferred stock, par value 0.001; 5,000,000 shares authorized (inclusive of series b preferred stock); 1,111,111 issued and zero outstanding | ||||||||||||||||||||||
series b preferred stock, par value 0.001; 5,000,000 shares authorized (inclusive of series a preferred stock); 555,555 issued and zero outstanding | ||||||||||||||||||||||
common stock | 47,000 | 45,000 | 42,000 | |||||||||||||||||||
stockholders’ equity - sum | 614,218,000 | 454,550,000 | 330,824,000 | |||||||||||||||||||
investments in marketable securities | 3,021,000 | 3,789,000 | 4,114,000 | 33,281,000 | 39,490,000 | 42,893,000 | 128,558,000 | 187,206,000 | ||||||||||||||
loan receivable – related party | 4,000,000 | 4,000,000 | 4,000,000 | |||||||||||||||||||
loan receivable, non-current | 25,040,000 | |||||||||||||||||||||
loan receivable - related party | 2,125,000 | 2,125,000 | 4,000,000 | |||||||||||||||||||
liabilities, mezzanine equity, and stockholders’ equity | ||||||||||||||||||||||
loans receivable – related parties | 4,129,000 | 4,145,000 | ||||||||||||||||||||
apollo medical holdings, inc. | ||||||||||||||||||||||
noncurrent assets | ||||||||||||||||||||||
total noncurrent assets | 444,082,000 | 423,880,000 | 473,005,000 | 478,909,000 | 447,575,000 | |||||||||||||||||
loans receivables | 594,000 | |||||||||||||||||||||
loans receivables – related parties | ||||||||||||||||||||||
investment in other entities – equity method | 37,372,000 | 42,615,000 | 27,220,000 | |||||||||||||||||||
loan receivable - short term | 50,000 | |||||||||||||||||||||
liabilities, mezzanine equity and stockholders’ equity | ||||||||||||||||||||||
noncurrent liabilities | ||||||||||||||||||||||
total noncurrent liabilities | 257,346,000 | |||||||||||||||||||||
noncontrolling interest | 87,000 | |||||||||||||||||||||
loan receivable | 6,425,000 | |||||||||||||||||||||
loan receivable – related parties |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities | ||||||||||||||||||||
net income | 13,131,000 | 6,562,000 | 1,077,000 | 10,216,000 | 6,221,000 | -7,777,000 | 18,981,000 | 21,866,000 | 16,862,000 | 27,973,000 | 15,663,000 | 14,307,000 | 27,396,000 | 10,591,000 | 12,073,000 | -19,309,000 | -5,385,000 | 59,530,000 | 14,458,000 | 12,908,000 |
adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||||||
depreciation and amortization | 15,479,000 | 16,401,000 | 15,596,000 | 6,903,000 | 6,849,000 | 8,126,000 | 7,264,000 | 7,441,000 | 5,096,000 | 4,305,000 | 4,249,000 | 4,292,000 | 4,755,000 | 4,351,000 | 4,374,000 | 4,412,000 | 4,671,000 | 4,237,000 | 4,197,000 | 4,346,000 |
amortization of debt issuance cost | 1,134,000 | 1,158,000 | 1,152,000 | 1,049,000 | 691,000 | 454,000 | 457,000 | 459,000 | 458,000 | 237,000 | 237,000 | 237,000 | 229,000 | 237,000 | 237,000 | |||||
share-based compensation | 9,895,000 | 11,382,000 | 7,700,000 | 11,708,000 | 7,811,000 | 15,235,000 | 6,163,000 | 7,390,000 | 5,748,000 | 5,706,000 | 4,213,000 | 3,445,000 | 3,502,000 | 3,920,000 | 3,055,000 | 2,423,000 | 1,420,000 | 1,556,000 | 1,346,000 | 825,000 |
non-cash lease expense | 2,005,000 | 2,299,000 | 1,789,000 | 1,272,000 | 1,287,000 | 1,332,000 | 1,314,000 | -523,000 | 3,155,000 | |||||||||||
deferred tax | 1,907,000 | 637,000 | -2,963,000 | -1,603,000 | -358,000 | 3,347,000 | -337,000 | -11,000 | -7,248,000 | -190,000 | -4,536,000 | 790,000 | -5,036,000 | 721,000 | 1,985,000 | -12,799,000 | -3,436,000 | 11,204,000 | -921,000 | -483,000 |
change in fair value of contingent consideration liabilities | 581,000 | 1,407,000 | ||||||||||||||||||
other | -2,564,000 | -7,268,000 | 1,051,000 | 4,467,000 | -557,000 | -3,781,000 | 1,303,000 | 296,000 | 6,795,000 | 0 | 0 | |||||||||
changes in operating assets and liabilities, net of business combinations | 26,488,000 | -15,446,000 | ||||||||||||||||||
net cash from operating activities | 68,056,000 | -2,886,000 | 9,956,000 | 90,900,000 | 16,627,000 | -10,948,000 | 33,981,000 | 23,188,000 | 5,977,000 | 15,405,000 | 25,802,000 | 7,720,000 | -35,870,000 | 9,021,000 | 24,038,000 | -12,190,000 | 51,239,000 | 21,334,000 | 9,952,000 | -2,601,000 |
capital expenditures | -4,000,000 | -3,064,000 | -2,552,000 | -1,420,000 | -3,070,000 | -2,531,000 | -2,295,000 | -2,836,000 | -4,105,000 | -11,340,000 | -14,851,000 | -3,209,000 | -1,356,000 | -17,489,000 | -2,803,000 | -9,056,000 | -7,266,000 | -98,000 | -611,000 | |
free cash flows | 64,056,000 | -5,950,000 | 7,404,000 | 89,480,000 | 13,557,000 | -13,479,000 | 31,686,000 | 20,352,000 | 11,300,000 | 14,462,000 | -7,131,000 | -39,079,000 | 7,665,000 | 6,549,000 | -14,993,000 | 42,183,000 | 14,068,000 | 9,854,000 | -3,212,000 | |
cash flows from investing activities | ||||||||||||||||||||
purchases of property and equipment | -4,000,000 | -3,064,000 | -2,552,000 | -1,420,000 | -3,070,000 | -2,531,000 | -2,295,000 | -2,836,000 | -369,000 | -4,105,000 | -11,340,000 | -6,027,000 | -3,209,000 | -1,356,000 | -17,489,000 | -2,803,000 | -9,056,000 | -7,266,000 | -98,000 | -611,000 |
net cash from investing activities | -2,844,000 | -1,057,000 | -534,471,000 | -1,077,000 | -2,394,000 | -33,324,000 | -8,107,000 | -79,925,000 | -71,039,000 | -34,875,000 | -5,186,000 | -14,035,000 | -8,086,000 | 7,497,000 | -19,725,000 | 39,084,000 | -12,742,000 | -10,494,000 | 692,000 | 29,096,000 |
cash flows from financing activities | ||||||||||||||||||||
dividends paid | -104,000 | -1,556,000 | -96,000 | -778,000 | -5,455,000 | -1,922,000 | -218,000 | -1,801,000 | -95,000 | -1,424,000 | -722,000 | -120,000 | -120,000 | -11,378,000 | -1,178,000 | 0 | -9,979,000 | -21,106,000 | -4,000 | -1,186,000 |
borrowings on debt | ||||||||||||||||||||
repayment of debt | -11,967,000 | |||||||||||||||||||
deferred financing cost | 0 | -1,964,000 | 0 | -17,241,000 | ||||||||||||||||
taxes paid from net share settlement of restricted stock | -1,172,000 | -607,000 | -509,000 | -1,001,000 | -4,052,000 | -687,000 | -391,000 | |||||||||||||
repurchase of treasury shares | -2,906,000 | -220,000 | -9,539,000 | |||||||||||||||||
net cash from financing activities | -15,960,000 | -26,337,000 | 648,491,000 | -8,638,000 | -44,170,000 | -15,267,000 | -3,190,000 | 47,252,000 | 106,351,000 | -510,000 | -963,000 | -7,099,000 | -6,251,000 | -20,237,000 | 532,000 | 1,435,000 | -11,016,000 | -39,429,000 | 1,262,000 | 647,000 |
net increase in cash, cash equivalents, and restricted cash | 49,252,000 | -30,280,000 | 123,976,000 | 81,185,000 | -29,937,000 | -3,719,000 | 4,845,000 | 28,329,000 | 27,481,000 | -28,589,000 | 11,906,000 | |||||||||
cash, cash equivalents, and restricted cash, beginning of period | 434,045,000 | 0 | 1,000 | 289,101,000 | 0 | 0 | 294,152,000 | 0 | 0 | 233,097,000 | 0 | 0 | 193,970,000 | |||||||
cash, cash equivalents, and restricted cash, end of period | 483,297,000 | 123,976,000 | 81,186,000 | 259,164,000 | 22,684,000 | -9,485,000 | 335,441,000 | -50,207,000 | -3,719,000 | 237,942,000 | 27,481,000 | -28,589,000 | 205,876,000 | |||||||
supplemental disclosures of cash flow information | ||||||||||||||||||||
cash paid for income taxes | 0 | 390,000 | 4,338,000 | 2,528,000 | 35,548,000 | 194,000 | 0 | 19,500,000 | 12,401,000 | 1,476,000 | 23,284,000 | 40,000 | 24,102,000 | |||||||
cash paid for interest | 14,723,000 | 15,583,000 | 16,649,000 | 6,175,000 | 7,360,000 | 7,229,000 | 8,577,000 | 8,183,000 | 6,430,000 | 3,406,000 | 3,273,000 | 2,991,000 | 2,155,000 | 1,386,000 | 845,000 | 828,000 | 823,000 | 1,230,000 | 1,277,000 | 1,549,000 |
supplemental disclosures of non-cash investing and financing activities | ||||||||||||||||||||
right-of-use assets obtained in exchange for operating lease liabilities | 350,000 | 4,095,000 | 670,000 | 814,000 | 5,642,000 | 2,751,000 | 4,910,000 | 5,925,000 | ||||||||||||
dividend paid in the form of common stock | 0 | |||||||||||||||||||
receivables | -10,368,000 | 85,000 | -28,965,000 | 9,077,000 | -26,373,000 | -2,123,000 | -11,529,000 | -44,673,000 | -711,000 | -585,000 | -9,390,000 | 11,087,000 | ||||||||
other receivables | 3,688,000 | -600,000 | -983,000 | -1,403,000 | 1,074,000 | 1,323,000 | -94,000 | -28,408,000 | 33,000 | -3,613,000 | -1,211,000 | -43,000 | -223,000 | -309,000 | ||||||
prepaid expenses and other current assets | 2,674,000 | -3,029,000 | -3,286,000 | -284,000 | -4,255,000 | 1,031,000 | -1,771,000 | -506,000 | -881,000 | -62,000 | 4,171,000 | -2,356,000 | 451,000 | -2,552,000 | 7,165,000 | -4,628,000 | ||||
other assets | -314,000 | -5,879,000 | -1,734,000 | -1,354,000 | 92,000 | -159,000 | 2,000 | -23,000 | -2,472,000 | -226,000 | 2,016,000 | -575,000 | -528,000 | -234,000 | -192,000 | -440,000 | ||||
accounts payable and accrued expenses | 8,000 | -56,785,000 | 198,000 | 24,763,000 | 905,000 | 1,745,000 | 1,653,000 | -4,517,000 | -13,416,000 | 10,446,000 | 3,735,000 | -11,145,000 | -2,622,000 | 13,069,000 | 3,915,000 | -4,440,000 | ||||
fiduciary accounts payable | -3,383,000 | 2,183,000 | -1,280,000 | -472,000 | 56,000 | -2,346,000 | -373,000 | 911,000 | 435,000 | -235,000 | -4,229,000 | 1,707,000 | -265,000 | 2,221,000 | -2,771,000 | 5,657,000 | ||||
medical liabilities | 3,319,000 | -10,947,000 | 10,766,000 | 11,559,000 | -808,000 | -3,227,000 | -3,806,000 | 17,141,000 | -17,615,000 | 15,132,000 | 39,974,000 | 12,912,000 | -16,610,000 | 7,828,000 | 1,149,000 | -7,125,000 | ||||
income taxes payable/receivable | -27,603,000 | 14,542,000 | 9,758,000 | |||||||||||||||||
operating lease liabilities | -1,090,000 | -1,214,000 | -1,214,000 | 686,000 | -3,083,000 | -1,906,000 | -1,221,000 | -2,088,000 | -805,000 | -1,609,000 | -645,000 | -687,000 | -830,000 | -839,000 | -859,000 | -863,000 | ||||
other liabilities | ||||||||||||||||||||
payments for business and asset acquisition, net of cash acquired | ||||||||||||||||||||
purchases of investments – equity method | -9,469,000 | |||||||||||||||||||
purchase of call option issued in conjunction with equity method investment | 0 | 0 | ||||||||||||||||||
issuance of loans receivable | -20,000,000 | |||||||||||||||||||
proceeds from sale of equity method investment | 0 | 0 | 0 | |||||||||||||||||
repayments on debt | ||||||||||||||||||||
payment of financing obligation | ||||||||||||||||||||
payment of contingent consideration liabilities | ||||||||||||||||||||
cash, cash equivalents, and restricted cash, beginning of year | ||||||||||||||||||||
cash, cash equivalents, and restricted cash, end of year | ||||||||||||||||||||
common stock issued in business combination | 0 | 0 | 0 | 21,952,000 | 0 | 0 | 1,000,000 | |||||||||||||
common stock issued for contingent consideration payment | 0 | 0 | ||||||||||||||||||
acquisition of business through loan conversion | ||||||||||||||||||||
draw on letter of credit through revolver loan | 0 | 0 | -27,000 | 4,759,000 | ||||||||||||||||
tax impact from apc dividends to apc shareholders | ||||||||||||||||||||
distribution of real estate investments | ||||||||||||||||||||
effective settlement of note payable upon consolidation | ||||||||||||||||||||
transfer of investment in privately held to equity method | ||||||||||||||||||||
repurchase of treasury shares outstanding payable | ||||||||||||||||||||
dividend paid in form of stock | ||||||||||||||||||||
payments for business acquisitions, net of cash acquired | ||||||||||||||||||||
purchase of investment – equity method | 0 | -325,000 | -11,724,000 | |||||||||||||||||
issuance of loan receivable | -658,000 | |||||||||||||||||||
borrowings on long-term debt | 707,300,000 | 0 | 412,000,000 | 0 | 1,555,000 | 60,320,000 | 110,000,000 | |||||||||||||
repayment of long-term debt | -51,966,000 | -3,125,000 | -428,232,000 | -3,750,000 | -7,500,000 | -3,500,000 | -149,000 | -159,000 | -153,000 | -3,514,000 | -148,000 | -52,000 | -46,000 | |||||||
payment of contingent liabilities | ||||||||||||||||||||
elimination of note payable upon consolidation | ||||||||||||||||||||
payments for business acquisition, net of cash acquired | -909,000 | -63,936,000 | -50,649,000 | -4,756,000 | -10,000 | -2,458,000 | ||||||||||||||
loss on debt extinguishment | 375,000 | |||||||||||||||||||
unrealized loss on investments | 44,000 | -316,000 | 561,000 | 123,000 | -1,099,000 | 1,413,000 | -270,000 | 5,755,000 | ||||||||||||
loss from equity method investments | 867,000 | -1,452,000 | -1,512,000 | -1,433,000 | 626,000 | -132,000 | 3,135,000 | 677,000 | ||||||||||||
changes in operating assets and liabilities, net of business combinations: | ||||||||||||||||||||
receivables, net – related parties | -6,589,000 | -7,299,000 | -4,128,000 | -7,943,000 | -9,730,000 | -9,681,000 | -5,286,000 | -6,865,000 | 15,141,000 | -1,896,000 | -17,612,000 | -7,741,000 | ||||||||
income taxes receivable | 3,514,000 | |||||||||||||||||||
other long-term liabilities | 531,000 | 595,000 | -464,000 | 298,000 | 2,748,000 | |||||||||||||||
proceeds from repayment of promissory notes, including those with related parties | 600,000 | 0 | 0 | |||||||||||||||||
purchase of marketable securities | -24,000 | -27,000 | -28,000 | -27,000 | -103,000 | -1,022,000 | -1,000,000 | 0 | ||||||||||||
distribution from investment - equity method | 100,000 | 0 | 200,000 | 200,000 | ||||||||||||||||
payment of finance lease obligations | -147,000 | -136,000 | -172,000 | -183,000 | -179,000 | -202,000 | -149,000 | -154,000 | -134,000 | -142,000 | -141,000 | -27,000 | -27,000 | -27,000 | ||||||
proceeds from espp purchases | 301,000 | 0 | ||||||||||||||||||
repurchase of subsidiary's shares | -1,316,000 | |||||||||||||||||||
proceeds from sale of non-controlling interest | 0 | 0 | 0 | 150,000 | 29,000 | 0 | 38,000 | |||||||||||||
purchase of non-controlling interest | -28,000 | -15,000 | 0 | 0 | -25,000 | 0 | -4,139,000 | 1,000 | -200,000 | |||||||||||
gain on debt extinguishment | 0 | |||||||||||||||||||
income from equity method investments | -1,564,000 | -1,353,000 | -902,000 | -632,000 | 2,103,000 | -2,723,000 | -2,484,000 | |||||||||||||
unrealized gain on interest rate swaps | -1,593,000 | |||||||||||||||||||
gain on sale or distribution of investments | ||||||||||||||||||||
loss on consolidation of equity method investment | ||||||||||||||||||||
changes in operating assets and liabilities, net of acquisition amounts: | ||||||||||||||||||||
receivable | -26,128,000 | |||||||||||||||||||
receivable, net – related parties | -3,374,000 | |||||||||||||||||||
other receivable | ||||||||||||||||||||
purchases of marketable securities | -21,000 | -26,991,000 | -339,000 | -338,000 | -332,000 | 0 | ||||||||||||||
proceeds from sale of marketable securities | 0 | -42,000 | 66,506,000 | 0 | 0 | 1,106,000 | ||||||||||||||
issuance of promissory notes | 0 | -5,000,000 | ||||||||||||||||||
purchases of investments – privately held | ||||||||||||||||||||
contribution to investment - equity method | -100,000 | -250,000 | -1,435,000 | |||||||||||||||||
repayments on long-term debt | ||||||||||||||||||||
proceeds from exercise of stock options and warrants | ||||||||||||||||||||
cost of debt issuances | ||||||||||||||||||||
cash, cash equivalents and restricted cash, end of year | ||||||||||||||||||||
cash paid for taxes | ||||||||||||||||||||
mortgage loan | 0 | |||||||||||||||||||
loan receivable, non-current | ||||||||||||||||||||
purchase of investments – privately held | 0 | |||||||||||||||||||
proceeds from the exercise of stock options | ||||||||||||||||||||
borrowings on loans | 1,415,000 | 117,000 | 1,617,000 | 749,000 | 515,000 | 722,000 | ||||||||||||||
net increase in cash and cash equivalents | 22,684,000 | -9,485,000 | 41,289,000 | 19,653,000 | -13,414,000 | |||||||||||||||
fixed assets obtained in exchange for finance lease liabilities | ||||||||||||||||||||
unrealized loss on interest rate swaps | -588,000 | 637,000 | -1,472,000 | |||||||||||||||||
proceeds from the exercise of stock options and warrants | 0 | 0 | 1,250,000 | 1,046,000 | 165,000 | 1,573,000 | 1,785,000 | 560,000 | 4,256,000 | |||||||||||
fixed asset obtained in exchange for finance lease liabilities | 0 | 0 | 398,000 | |||||||||||||||||
proceeds from repayment of loans receivable – related parties | 6,000 | 57,000 | 2,000 | 2,141,000 | 21,000 | 4,011,000 | 19,000 | 10,000 | 15,000 | 16,000 | ||||||||||
deposit for purchase of property | -8,824,000 | |||||||||||||||||||
business acquisition in accounts payable and accrued liabilities | 63,935,000 | |||||||||||||||||||
purchase of investments - equity method in accounts payable and accrued liabilities and other liabilities | 9,487,000 | |||||||||||||||||||
gain on sale of equity securities | ||||||||||||||||||||
right-of-use assets | 1,983,000 | 1,227,000 | 2,013,000 | 553,000 | 1,618,000 | 672,000 | 693,000 | 794,000 | 810,000 | 836,000 | 724,000 | |||||||||
payments for business and asset acquisitions, net of cash acquired | -5,024,000 | |||||||||||||||||||
purchase of investments - privately held | 0 | |||||||||||||||||||
purchase of investments - equity method | 0 | |||||||||||||||||||
repurchase of shares | -150,000 | -168,000 | -9,250,000 | -230,000 | -2,758,000 | -2,639,000 | -342,000 | |||||||||||||
net decrease in cash and cash equivalents | ||||||||||||||||||||
cash and cash equivalents beginning of period | 0 | 0 | 288,027,000 | |||||||||||||||||
cash and cash equivalents end of period | -19,980,000 | 19,653,000 | 274,613,000 | |||||||||||||||||
supplementary disclosures of cash flow information | ||||||||||||||||||||
cashless exercise of warrants | ||||||||||||||||||||
tax impact from dividends | ||||||||||||||||||||
income taxes payable | 4,007,000 | -1,263,000 | -17,533,000 | 4,241,000 | -3,321,000 | 1,709,000 | -9,844,000 | 7,835,000 | -11,946,000 | |||||||||||
non-cash business acquisition | 3,844,000 | |||||||||||||||||||
gain on sale of investments | ||||||||||||||||||||
impairment of beneficial interest | 0 | 0 | ||||||||||||||||||
cash received from consolidation of vie | 0 | |||||||||||||||||||
proceeds from sale of shares | 1,000 | -1,000 | ||||||||||||||||||
payment of debt issuance costs | 0 | |||||||||||||||||||
net increase in cash, cash equivalents and restricted cash | 27,142,000 | |||||||||||||||||||
dividend declared included in dividend payable | 0 | 21,000 | 0 | |||||||||||||||||
deferred tax liability adjustment to goodwill | ||||||||||||||||||||
cancellation of restricted stock awards | 0 | 190,000 | 0 | 144,000 | ||||||||||||||||
unrealized loss from investment in equity securities | 3,103,000 | 10,556,000 | 33,671,000 | 60,943,000 | -12,000 | |||||||||||||||
prepayment for investment purchase | ||||||||||||||||||||
payments for business acquisition, net of cash acquired and shares issued | -999,000 | |||||||||||||||||||
distribution to non-controlling interest | ||||||||||||||||||||
supplementary disclosures of cash flow information: | ||||||||||||||||||||
loss of disposal of property and equipment | ||||||||||||||||||||
impairment of goodwill and intangible assets | ||||||||||||||||||||
provision for doubtful accounts | ||||||||||||||||||||
gain on sale of equity method investment | 0 | |||||||||||||||||||
gain on consolidation of equity method investment | ||||||||||||||||||||
gain on contingent equity securities | ||||||||||||||||||||
gain on loan assumption | ||||||||||||||||||||
gain from investment in warrants | ||||||||||||||||||||
loss in interest rate swaps | ||||||||||||||||||||
proceeds from repayment of loans receivable - related parties | ||||||||||||||||||||
advances on loans receivable | ||||||||||||||||||||
dividends received from equity method investments | ||||||||||||||||||||
proceeds from sale of fixed assets | ||||||||||||||||||||
purchases of investments in privately held entities | ||||||||||||||||||||
cash recorded from consolidation of vie | ||||||||||||||||||||
repayment of term loan | -2,434,000 | -2,375,000 | ||||||||||||||||||
change in non-controlling interest capital | ||||||||||||||||||||
borrowings on line of credit | ||||||||||||||||||||
repayments on bank loan and lines of credit | ||||||||||||||||||||
payment of capital lease obligations | ||||||||||||||||||||
proceeds from common stock offering | ||||||||||||||||||||
repurchase of common shares | ||||||||||||||||||||
cost of debt and equity issuances | ||||||||||||||||||||
issuance of financing obligation for business combinations | ||||||||||||||||||||
apc stock issued in exchange for amg | ||||||||||||||||||||
reclassification of liability for equity shares | ||||||||||||||||||||
deferred tax liability adjustment related to warrant exercises | 217,000 | |||||||||||||||||||
preferred shares received from sale of equity method investment | 0 | |||||||||||||||||||
beneficial interest acquired from sale of equity method investment | ||||||||||||||||||||
amortization of debt issuance costs | 159,000 | 390,000 | 351,000 | |||||||||||||||||
loss on interest rate swaps | -126,000 | |||||||||||||||||||
distribution to noncontrolling interest | ||||||||||||||||||||
proceeds from sale of noncontrolling interest | 10,000 | 0 | 38,000 | |||||||||||||||||
borrowings on revolver | 0 | |||||||||||||||||||
preferred shares received from sale of equity investment | ||||||||||||||||||||
gain on sale of equity method investments | ||||||||||||||||||||
purchase of noncontrolling interest | 150,000 | -225,000 | ||||||||||||||||||
unrealized gain from investment in equity securities | -9,000 | |||||||||||||||||||
loss on disposal of property and equipment | ||||||||||||||||||||
capitation incentives payable | ||||||||||||||||||||
change in noncontrolling interest capital | ||||||||||||||||||||
cash, cash equivalents and restricted cash, beginning of year | ||||||||||||||||||||
deferred tax liability adjusted to goodwill | ||||||||||||||||||||
purchase price adjustment for acceleration of vested stock options | ||||||||||||||||||||
conversion of loan receivable to investment in accountable health care, ipa | ||||||||||||||||||||
reclassification of dividends related to share repurchase | ||||||||||||||||||||
reclassification of aps noncontrolling interest to equity related to purchase of additional shares | ||||||||||||||||||||
impairment of intangibles | ||||||||||||||||||||
dividend received | ||||||||||||||||||||
repayment of bank loan and lines of credit | ||||||||||||||||||||
cost of debt and equity issuance costs | ||||||||||||||||||||
cash, cash equivalents and restricted cash, beginning of period | ||||||||||||||||||||
cash, cash equivalents and restricted cash, end of period |